New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:37 EDTPRGOPerrigo near-term outlook has improved, says RBC Capital
RBC Capital expects Perrigo to benefit from several positive catalysts, including lower buyside expectations, tailwinds for the company's consumer health business, and increased focus on its Tysabri SPMS opportunity. The firm keeps a $160 price target and Outperform rating on the shares.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
06:13 EDTPRGOPfizer insists Allergan deal won't be thwarted by U.S. politicians, FT says
Pfizer (PFE) has insisted that its $160B acquisition of Allergan (AGN) will not be stifled by political opposition, amid criticism that the deal will cost the U.S. Treasury billions of dollars in future tax revenues, the Financial Times reports. Pfizer CEO Ian Read also reiterated his intention to postpone until 2018 a decision on whether to break of the combined entity into two or three smaller companies, but has said that he would be open to offers for its generics unit, the report says. Mylan (MYL) has been connected to a potential acquisition of Pfizer's generic drugs business after it failed in its attempt to buy Perrigo (PRGO) last year, the report says. Reference Link
January 26, 2016
12:12 EDTPRGOEndo spike attributed to takeover speculation
The midday spike in shares of Endo International (ENDP) is being attributed to takeover speculation. Conjecture has Perrigo (PRGO) interested in a potential acquisition of Endo, trading sources tell The Fly. Shares of Endo are up $1.26 to $59.10 in midday trading. The Fly, in fulfilling its mission of explaining stock movement, often comes across the many unconfirmed rumors being passed through trading desks and social media platforms. On the occasion that rumors or speculation appear on The Fly's news feed, it should be viewed not as giving credence to the conjecture, rather as simply highlighting its impact on the stock prices of the companies involved.
January 25, 2016
08:31 EDTPRGOPerrigo completes acquisition of generic Retin-A from Matawan
Perrigo announced that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A from Matawan Pharmaceuticals. Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for the topical treatment of acne vulgaris, were approximately $290M for the 12 months ending November 2015.The transaction is expected to immediately exceed Perrigo's ROIC threshold and add more than 20c in adjusted EPS within the first 12 months post-close after the exclusion of estimates for intangible amortization, transaction costs and integration related expenses. Perrigo Chairman and CEO Joseph C. Papa commented, "We are excited to complete this transaction; bringing a high barrier-to-entry, margin-enhancing product and greater reach to the extended topicals portfolio. This acquisition further strengthens Perrigo's strategic position as we continue our mission of providing Quality Affordable Healthcare Products(R) to consumers around the world."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use